The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Promising BCMA-targeting CAR-T cells for relapsed myeloma
Elisabet Manasanch, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a Phase I first-in-human trial (NCT03602612) of FHVH-BCMA-T, a BCMA-targeting CAR T-cell therapy with a novel heavy chain only antigen recognition domain for the treatment of relapsed multiple myeloma. FHVH-BCMA-T was designed to reduce the risk of host immune responses against the CAR T-cells. The trial evaluated efficacy and tolerability of the treatment at dose levels, establishing 6 x 10^6 CAR+ T cells/kg as the maximum feasible dose. The results showed deep and durable responses, as well as a promising safety profile. The substantial overall response rate seen in this difficult to treat population supports FHVH-BCMA-T use, and enrollment into an expansion cohort has begun. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
